Dr. Liu on Medical Advancements for Neuroendocrine Tumors

Eric Liu, MD, FACS
Published: Friday, Oct 16, 2015



Eric Liu, MD, FACS, surgeon, neuroendocrine tumors, Rocky Mountain Cancer Centers, discusses some of the most recent medical advancements in the field of neuroendocrine tumors (NETs).

Somatostatin analogs, a synthetic hormone therapy, have been a standard treatment for NETs, Liu explains, while a new somatostatin analog, somatuline, has also been shown to slow tumor growth. Additional recently approved agents for pancreatic NETS include sunitinib and everolimus.

Liu mentions other agents that are pushing the field forward, including telotristat etiprate for the treatment of carcinoid syndrome, and Lutathera, described as a radioactive version of octreotide, also shown to slow tumor growth.

<<< View more from the 2015 NANETS Symposium



Eric Liu, MD, FACS, surgeon, neuroendocrine tumors, Rocky Mountain Cancer Centers, discusses some of the most recent medical advancements in the field of neuroendocrine tumors (NETs).

Somatostatin analogs, a synthetic hormone therapy, have been a standard treatment for NETs, Liu explains, while a new somatostatin analog, somatuline, has also been shown to slow tumor growth. Additional recently approved agents for pancreatic NETS include sunitinib and everolimus.

Liu mentions other agents that are pushing the field forward, including telotristat etiprate for the treatment of carcinoid syndrome, and Lutathera, described as a radioactive version of octreotide, also shown to slow tumor growth.

<<< View more from the 2015 NANETS Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x